Precision Genetics Launches a New Diagnostic to Detect COVID-19 and the Flu

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

November 10, 2020

Precision Genetics, a leader in the molecular laboratory and technology industries, announces today the launch of a new diagnostic test that simultaneously detects SARS-CoV-2 and Influenza A/B strains in upper respiratory tract specimens.

Precision Genetics notes the test is available to health systems, providers, employers, and academic institutions alike.

Precision Genetics’ capabilities are essential for accurately detecting patients with COVID-19 and/or the flu. “By utilizing our high-complexity laboratory and testing methods, we can quickly and accurately distinguish between these viral infections,” said Nate Wilbourne, founder and CEO of Precision Genetics. “Our goal as a molecular laboratory is to ensure the highest levels of quality and efficiency to our clinical partners.”

The addition of this combination test comes just in time for the flu season.  “Most current testing looks only for COVID-19. As influenza infection rates rise, testing individuals only for Covid-19 is insufficient to distinguish between various viral illnesses of the upper respiratory tract,” said John Wrangle, M.D, Chief Medical Officer of Precision Genetics.  “Knowing which virus a patient is infected with may help treating physicians, health professionals and health departments decide on the best course of treatment, surveillance and contact tracing.”

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles